Research stage
01Model evidence from diverse MRI cohorts
- Scanner-aware MRI normalisation
- Rare disease pattern discovery
- Similarity search against confirmed cases
AI for rare disease prediction from MRI
Rare neurological diseases often take years to diagnose. Neuvara is building AI systems that help uncover diagnostic signals hidden within medical imaging and clinical data.
Mission
Rare disease prediction from MRI + clinical data
Current stage
Research-stage model validation
Clinical posture
Decision support with human oversight
Why Neuvara
Built for the realities of rare neurological disease research.
Neuvara focuses on the parts of medical AI that matter before clinical deployment: signal quality, clinical context, scanner variation, and evidence that can be reviewed by specialists.
01
MRI signal understanding
Model development starts with scanner-aware MRI representations, sequence metadata, and anatomical context rather than treating images as generic pixels.
02
Multimodal clinical data integration
Clinical history, symptoms, scanner metadata, and imaging evidence are designed to be evaluated together so research outputs reflect patient context.
03
Rare disease pattern detection
The platform is oriented around subtle, low-prevalence neurological patterns where cohort comparison and evidence retrieval matter.
04
Research validation framework
Neuvara is structured for staged retrospective validation, scanner-diverse evaluation, model cards, and clinician-reviewed outputs before clinical use.
Platform
A prediction layer for rare neurological disease.
Neuvara is being developed as a research platform for AI models that can evaluate rare disease risk signals from MRI scans and supporting clinical data while keeping clinicians in control of interpretation.
Validation stage
02Clinician-reviewed prediction workflows
- Retrospective validation studies
- MRI + clinical data fusion
- Explainable prediction outputs
- Human-in-the-loop review
Platform stage
03AI models for earlier rare disease risk signals
- Brain MRI foundation models
- Longitudinal disease modelling
- Privacy-conscious hospital deployment
- Earlier prediction of rare disease risk
Clinical problem
Prediction models need to handle messy real-world MRI.
Rare disease signals can be subtle, distributed across anatomy, and difficult to compare against prior confirmed cases.
Brain MRI varies across vendors, field strengths, protocols, and acquisition settings, making naive models brittle across institutions.
Clinical context matters: prediction should combine imaging evidence with symptoms, history, metadata, and specialist review.
Architecture
Scanner-aware models for MRI and clinical data.
The platform combines MRI harmonisation, volumetric representation learning, clinical data fusion, and cohort retrieval to produce evidence that can be evaluated by specialists.
MRI harmonisation
MRI scans vary by manufacturer, field strength, sequence, echo time, repetition time, and protocol. Neuvara uses scanner-aware preprocessing before downstream modelling.
Shared volumetric backbone
A shared 3D model learns neuroimaging representations that can support rare disease prediction, similarity search, and future validated neurological workflows.
MRI + clinical data fusion
Clinical metadata and imaging features are combined so model outputs can reflect both anatomy and patient context instead of MRI alone.
Competitive advantage
Differentiated by evidence, context, and rare disease focus.
MRI + clinical data fusion
Neuvara is being built around multimodal evidence rather than imaging-only outputs, supporting diagnostic research where context changes interpretation.
Rare disease focus
The research direction prioritises conditions where signals are sparse, delayed diagnosis is common, and comparison against confirmed cases can be valuable.
Explainable evidence generation
Outputs are designed to include reviewable evidence such as region-level signals, comparable cohorts, and confidence context for specialist evaluation.
Longitudinal modelling direction
The future platform direction includes progression-aware modelling across imaging history and clinical timelines, subject to partner data and validation.
Prediction workflow
From MRI and clinical context to reviewable evidence.
Neuvara is being built to surface risk-oriented model signals, comparable confirmed cases, and explainable evidence for research and specialist review.
Prediction workflowClinician-in-the-loop
Active layer
MRI + clinical data
Brain MRI volumes are paired with structured clinical context such as symptoms, history, and acquisition metadata.
Multimodal patient context
Prediction should be inspectable, not opaque.
Risk signals are paired with heatmaps, comparable cases, and confidence context so clinicians and researchers can understand why a pattern was surfaced.
Region-level evidence
Similarity-ranked cohorts
Clinician-facing outputs
Prediction workspace
Select a layer
Primary signal
Subtle MRI patterns combined with structured clinical context
Output layer
Risk-oriented prediction signal with explainable supporting evidence
Validation focus
Retrospective rare disease and paediatric neuroimaging cohorts
Validation and trust
Built for evidence generation before clinical deployment.
Neuvara is research-stage. The platform is intended to support validation studies, clinical oversight, and privacy-conscious workflows before any clinical use.
Evidence before deployment
Validation is staged around retrospective cohorts, scanner-diverse datasets, and prospective partner studies before clinical use.
Research-stage platform
Neuvara is being built for validation and decision support. It is not positioned as a replacement for specialist judgement.
Human oversight
Predictions are paired with model evidence, similar cases, and interpretability overlays for clinician review.
Privacy-conscious architecture
The long-term direction supports privacy-preserving learning where patient data can remain within hospital environments.
Governance by design
The platform is intended to prioritise minimisation, auditability, secure handling, and clear clinical accountability.
Validation approach
A research-stage process for evaluating model reliability.
1
Diverse MRI datasets
Benchmark model behaviour across public research datasets and partner-ready cohorts with variation in acquisition protocols and patient populations.
2
Multi-centre data strategy
Prioritise retrospective studies that expose models to different institutions, scanners, and clinical workflows before any deployment claims.
3
Scanner harmonisation
Evaluate harmonisation steps for manufacturer, field strength, sequence, and protocol differences so downstream models remain robust.
4
Clinical outcome evaluation
Connect model outputs to clearly defined research endpoints, cohort labels, and outcome review rather than relying on visual plausibility.
5
Human oversight
Keep outputs positioned for specialist review, with evidence context and limitations documented before clinical decision-support use.
Research roadmap
A staged path from MRI infrastructure to prospective studies.
Phase 1
MRI data infrastructure
Build ingestion, metadata capture, preprocessing, and dataset documentation workflows for research-grade MRI cohorts.
Phase 2
Scanner harmonisation
Evaluate harmonisation methods across scanner manufacturers, field strengths, sequences, and acquisition protocols.
Phase 3
Multimodal modelling
Combine volumetric MRI representations with clinical context, metadata, and cohort retrieval for research prediction workflows.
Phase 4
Clinical validation
Run retrospective studies with defined endpoints, scanner-diverse cohorts, model cards, and specialist review of evidence outputs.
Phase 5
Prospective deployment studies
Move toward privacy-conscious hospital evaluation and prospective workflow studies after retrospective evidence is established.
Partner with Neuvara
Help validate AI models for rare disease prediction.
We are seeking research, clinical, hospital, and strategic partners for retrospective studies, scanner generalisation research, and privacy-conscious evaluation pathways.